| Schedule of segments |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | | Diagnostics | | Therapeutic
Devices | | Development
Services | | Consolidated | | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | Net revenue | | $ | 1,385 | | $ | 781 | | $ | 6,754 | | $ | 6,183 | | $ | 1,373 | | $ | - | | $ | 9,512 | | $ | 6,964 | Cost of revenue | | | 630 | | | 589 | | | 2,237 | | | 1,709 | | | 604 | | | - | | | 3,471 | | | 2,298 | Gross profit | | $ | 755 | | $ | 192 | | $ | 4,517 | | $ | 4,474 | | $ | 769 | | $ | - | | $ | 6,041 | | $ | 4,666 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, | | | Diagnostics | | Therapeutic
Devices | | Development
Services | | Consolidated | | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | Net revenue | | $ | 2,351 | | $ | 1,340 | | $ | 12,575 | | $ | 12,124 | | $ | 3,385 | | $ | - | | $ | 18,311 | | $ | 13,464 | Cost of revenue | | | 1,217 | | | 1,146 | | | 4,031 | | | 3,245 | | | 1,538 | | | - | | | 6,786 | | | 4,391 | Gross profit | | $ | 1,134 | | $ | 194 | | $ | 8,544 | | $ | 8,879 | | $ | 1,847 | | $ | - | | $ | 11,525 | | $ | 9,073 |
|